Physician

David C. Molthrop, M.D.

According to 2025 Medicare claims, David Molthrop, M.D. (NPI: 1194783027) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Orange, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32789-2988.

Molthrop's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,032 traditional Medicare patients, billed 213,234 HCPCS/CPT codes, and received $4,050,300 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,526 prescription claims across 494 beneficiaries totaling $6,734,311 in drug costs, led by Revlimid (Lenalidomide). DME data shows 126 claims. Open Payments data shows 22 records totaling $571. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,617,745 to $4,050,300. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,857,083 to $6,734,311. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,021	143,140	$1,617,745
2016	1,113	170,099	$2,061,961
2017	1,140	137,016	$2,232,273
2018	1,243	192,130	$2,826,354
2019	1,170	190,404	$2,263,660
2020	1,006	140,122	$2,330,257
2021	990	149,985	$2,486,755
2022	947	162,075	$2,734,250
2023	987	210,720	$3,246,686
2024	1,032	213,234	$4,050,300

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	326	1,742	$1,857,083
2016	278	1,221	$1,835,134
2017	293	1,294	$2,077,186
2018	300	1,512	$3,346,719
2019	322	1,781	$4,435,014
2020	346	1,705	$3,875,158
2021	380	1,896	$4,325,653
2022	413	2,069	$4,341,218
2023	430	2,188	$4,136,798
2024	494	2,526	$6,734,311

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	40	$25,216
2016	N/R	N/R	N/R
2017	N/R	13	$7,185
2018	N/R	87	$11,886
2019	N/R	66	$7,437
2020	N/R	72	$4,774
2021	N/R	48	$3,111
2022	N/R	76	$2,203
2023	N/R	85	$19,105
2024	N/R	126	$3,060

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	371	952	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	623	926	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	650	1,178	$13
36415	Insertion of needle into vein for collection of blood sample	830	2,670	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	824	2,804	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	93	2,219	$1,340,372
Brukinsa	Zanubrutinib	87	2,610	$1,109,358
Ibrance	Palbociclib	69	1,708	$928,965
Imbruvica	Ibrutinib	35	1,004	$566,790
Jakafi	Ruxolitinib Phosphate	29	870	$527,903

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	44	$1,628
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	52	$627
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	19	$616
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$188

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	22	$571	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David C. Molthrop, M.D.?

Tedicare shows public-source Medicare data for David C. Molthrop, M.D. (NPI 1194783027), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David C. Molthrop, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David C. Molthrop, M.D.?

David C. Molthrop, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does David C. Molthrop, M.D. have Open Payments data?

David C. Molthrop, M.D. has 22 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.